Objective:
To advance danegaptide into a Phase II clinical trial for non-proliferative diabetic retinopathy (NPDR).
Approach:
- Funding Details: Breye Therapeutics raised €67.5 million in an oversubscribed Series A financing round co-led by Mission BioCapital and Novo Holdings.
- Clinical Development: The funding will initiate a randomized Phase II study of danegaptide in NPDR patients in 2027.
- Therapeutic Mechanism: Danegaptide is an oral small molecule aimed at stabilizing retinal vasculature and preventing capillary breakdown.
- Previous Study Results: A Phase Ib study in 2025 showed danegaptide was well tolerated and indicated reduced vascular leakage.
Key Findings:
- Danegaptide represents a potentially non-invasive treatment for early-stage diabetic retinopathy.
- Current treatment options for diabetic retinopathy are limited, primarily involving intravitreal injections.
Interpretation:
The financing enables the advancement of danegaptide as a patient-friendly treatment option for diabetic retinopathy.
Limitations:
- The Phase II study is planned for 2027, indicating a delay before potential clinical application.
Conclusion:
Breye is also developing additional therapies for age-related macular degeneration and glaucoma.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
